Tag: Antibody-Drug Conjugates
-
Seagen v. Daiichi Sankyo: Federal Circuit Reverses $41M Verdict on Written Description
The Federal Circuit’s December 2, 2025 decision in Seagen Inc. v. Daiichi Sankyo Co., No. 23-2424, continues a noticeable and consequential trend: the court’s growing willingness to overturn jury verdicts on written description and enablement grounds as a matter of law. In reversing a $41 million verdict and vacating findings of willful infringement, the panel…